Ibrutinib does not have clinically relevant interactions with oral contraceptives or substrates of CYP3A and CYP2B6

Ibrutinib may inhibit intestinal CYP3A4 and induce CYP2B6 and/or CYP3A. Secondary to potential induction, ibrutinib may reduce the exposure and effectiveness of oral contraceptives (OCs). This phase I study evaluated the effect of ibrutinib on the pharmacokinetics of the CYP2B6 substrate bupropion,...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Pharmacol Res Perspect
Hlavní autoři: de Jong, Jan, Mitselos, Anna, Jurczak, Wojciech, Cordoba, Raul, Panizo, Carlos, Wrobel, Tomasz, Dlugosz‐Danecka, Monika, Jiao, James, Sukbuntherng, Juthamas, Ouellet, Daniele, Hellemans, Peter
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2020
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7506988/
https://ncbi.nlm.nih.gov/pubmed/32945596
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/prp2.649
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky